Omega-3 fatty acids, acute coronary syndrome, and sudden death

William Harris, Clemens von Schacky

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Omega-3 fatty acids (FAs) are currently recommended to reduce the risk of cardiovascular diseases. These recommendations are based on randomized trials, prospective cohort studies, and case-control data and are supported by experimental studies in humans, animals, and isolated cells. Raising tissue levels of omega-3 FAs reduces the risk of sudden cardiac death, most likely due to reduced susceptibility to fatal arrhythmias, but the effect of these FAs on the risk of myocardial infarction per se is less clear. Reductions in nonfatal events have not typically been seen in randomized trials, but case-control and prospective cohort studies support such an effect. Future studies should assess tissue levels of omega-3 FAs to more precisely estimate exposure and to more clearly define the relations between omega-3 status and the risk of fatal or nonfatal cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)161-166
Number of pages6
JournalCurrent Cardiovascular Risk Reports
Volume2
Issue number2
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Acute Coronary Syndrome
Sudden Death
Cohort Studies
Cardiovascular Diseases
Prospective Studies
Sudden Cardiac Death
Cardiac Arrhythmias
Fatty Acids
Myocardial Infarction

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Omega-3 fatty acids, acute coronary syndrome, and sudden death. / Harris, William; von Schacky, Clemens.

In: Current Cardiovascular Risk Reports, Vol. 2, No. 2, 2008, p. 161-166.

Research output: Contribution to journalArticle

Harris, William ; von Schacky, Clemens. / Omega-3 fatty acids, acute coronary syndrome, and sudden death. In: Current Cardiovascular Risk Reports. 2008 ; Vol. 2, No. 2. pp. 161-166.
@article{a0a86c42187242beb41801a279ccf3d9,
title = "Omega-3 fatty acids, acute coronary syndrome, and sudden death",
abstract = "Omega-3 fatty acids (FAs) are currently recommended to reduce the risk of cardiovascular diseases. These recommendations are based on randomized trials, prospective cohort studies, and case-control data and are supported by experimental studies in humans, animals, and isolated cells. Raising tissue levels of omega-3 FAs reduces the risk of sudden cardiac death, most likely due to reduced susceptibility to fatal arrhythmias, but the effect of these FAs on the risk of myocardial infarction per se is less clear. Reductions in nonfatal events have not typically been seen in randomized trials, but case-control and prospective cohort studies support such an effect. Future studies should assess tissue levels of omega-3 FAs to more precisely estimate exposure and to more clearly define the relations between omega-3 status and the risk of fatal or nonfatal cardiovascular diseases.",
author = "William Harris and {von Schacky}, Clemens",
year = "2008",
doi = "10.1007/s12170-008-0029-9",
language = "English (US)",
volume = "2",
pages = "161--166",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Omega-3 fatty acids, acute coronary syndrome, and sudden death

AU - Harris, William

AU - von Schacky, Clemens

PY - 2008

Y1 - 2008

N2 - Omega-3 fatty acids (FAs) are currently recommended to reduce the risk of cardiovascular diseases. These recommendations are based on randomized trials, prospective cohort studies, and case-control data and are supported by experimental studies in humans, animals, and isolated cells. Raising tissue levels of omega-3 FAs reduces the risk of sudden cardiac death, most likely due to reduced susceptibility to fatal arrhythmias, but the effect of these FAs on the risk of myocardial infarction per se is less clear. Reductions in nonfatal events have not typically been seen in randomized trials, but case-control and prospective cohort studies support such an effect. Future studies should assess tissue levels of omega-3 FAs to more precisely estimate exposure and to more clearly define the relations between omega-3 status and the risk of fatal or nonfatal cardiovascular diseases.

AB - Omega-3 fatty acids (FAs) are currently recommended to reduce the risk of cardiovascular diseases. These recommendations are based on randomized trials, prospective cohort studies, and case-control data and are supported by experimental studies in humans, animals, and isolated cells. Raising tissue levels of omega-3 FAs reduces the risk of sudden cardiac death, most likely due to reduced susceptibility to fatal arrhythmias, but the effect of these FAs on the risk of myocardial infarction per se is less clear. Reductions in nonfatal events have not typically been seen in randomized trials, but case-control and prospective cohort studies support such an effect. Future studies should assess tissue levels of omega-3 FAs to more precisely estimate exposure and to more clearly define the relations between omega-3 status and the risk of fatal or nonfatal cardiovascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=51349127005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349127005&partnerID=8YFLogxK

U2 - 10.1007/s12170-008-0029-9

DO - 10.1007/s12170-008-0029-9

M3 - Article

AN - SCOPUS:51349127005

VL - 2

SP - 161

EP - 166

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 2

ER -